Guardant Health: A Landmark Quarter Transforms the Story
FDA approval, ACS inclusion, and UnitedHealth coverage propel the stock and lift guidance
GH · Earnings Call · 2026-07-30
Guardant Health delivered a defining quarter, with revenue up 44% year-over-year to $335 million, and the stock surging 117% over the past 90 days — a reflection of three rare, company-specific catalysts converging. The Guardant360 Liquid CDx received FDA approval, Shield was added to the American Cancer Society guidelines, and UnitedHealth announced it will start covering Shield in August. These are not incremental steps; they represent a strategic inflection for the company.
A Regulatory Milestone
The FDA approval of Guardant360 Liquid CDx is a landmark event. As co-CEO Helmy Eltoukhy noted,
The FDA approval in the second quarter represents one of the most significant regulatory milestones in our company's history
. The new test integrates genomic and epigenomic content, and management expects ADLT designation in early 2027, which would lift the Medicare price toward $8,455 and potentially push Guardant360 ASP to around $5,000 over time. This was not baked into prior guidance — it is upside.
Market Access Breakthroughs
The ACS guideline inclusion — announced in May — and the UnitedHealth coverage decision came sooner than expected. In the prior quarter's call, AmirAli Talasaz said, “It's coming. It's coming now probably for over a year... it should be any day” — AmirAli Talasaz, Co-CEO · 2026-05-07. Now that it's here, roughly 60% of the U.S. screening market is covered for Shield, opening the under-65 commercial segment. This directly addresses the ASP and volume concerns flagged in past calls. As AmirAli put it, “UnitedHealth Group, the largest commercial insurer in the United States, announced it will begin covering Shield for colorectal cancer screening in adults 45 and older” — AmirAli Talasaz, Co-CEO · 2026-07-30.
These wins were not reflected in the company's conservative stance earlier this year. In the Q1 call, AmirAli said, “we are not counting on any kind of upside associated with the ACS guideline” — AmirAli Talasaz, Co-CEO · 2026-05-07. Now they are, and the full-year volume guide for Shield was raised by 40,000 tests.
Efficiency and Profitability Levers
The lower-COGS Shield workflow, approved by the FDA, is expected to cut cost per test by roughly 15% by year-end, supporting the path to $200 cost per test by 2028. This aligns with management's focus on cash flow breakeven. The company's gross margin has already improved to 65.2% in Q1 2026, and the trend is upward. Quarterly revenue has grown from $302M in Q1 2026 to $335M in Q2 2026, a 44% year-over-year increase, with oncology volume up 63%. The lower COGS Shield workflow and a completed NovaSeq X transition for Guardant360 are operational levers that should drive margin expansion.
In summary, Guardant Health has transformed from a promising diagnostics platform into a commercial-scale franchise. The combination of regulatory approval, guideline inclusion, and a major insurer win — all within one quarter — is rare and the stock's dramatic re-rating is justified. The company is now executing on a playbook that could lead to sustained growth and a path to profitability.